Therapy Areas: Vaccines
Data from Moderna's COVID-19 vaccine trial for young children expected in March 2022
13 January 2022 -

US pharmaceutical company Moderna Inc (Nasdaq:MRNA) expects to report data from its COVID-19 vaccine trial in children aged two to five years in March 2022, Reuters news agency reported on Thursday.

According to Moderna, if the data is supportive and subject to regulatory consultation, it may then proceed with regulatory filings for children in this age group.

Moderna's mRNA COVID-19 vaccine is already authorised in Europe, the UK, Australia and Canada for adolescents aged 12 to 17 years.

In the United States, the Moderna vaccine is authorised by Food and Drug Administration as primary two-dose regimen and booster dose for adults 18 years and older. The company is yet to get authorisation from the US regulator for use of its vaccine in children.